Clinical-Grade Plasmalogens

 

MLD is developing clinical-grade synthetic plasmalogen therapies for the treatment of Rhizomelic Chondrodysplasia Punctata, alzheimer’s disease, multiple sclerosis, parkinson’s and other neurological conditions*

 
 

*MLD’s plasmalogen drugs are currently undergoing required formal regulatory safety and efficacy studies and are not currently available to the public.

 
neuron_banner_inversed.png
 
 

News

 

Catch up on our latest whereabouts and milestones here!

News
MLD attending World Orphan Drug Congress 2024
MLD attending World Orphan Drug Congress 2024
Read More →
Rare Disease Day 2024 Coloring Contest Rules
Rare Disease Day 2024 Coloring Contest Rules
Read More →
MLD Presenting at AD/PD Conference
MLD Presenting at AD/PD Conference
Read More →
MLD Announces Completion of Dosing with Plasmalogen-precursor PPI-1011 in its Phase I Clinical Trial
MLD Announces Completion of Dosing with Plasmalogen-precursor PPI-1011 in its Phase I Clinical Trial
Read More →
Multiple ascending dose study of PPI-1011 begins dosing
Multiple ascending dose study of PPI-1011 begins dosing
Read More →
MLD to attend Canadian Conference on Dementia
MLD to attend Canadian Conference on Dementia
Read More →
SASKATOON-BASED BIOPHARMA COMPANY MED-LIFE DISCOVERIES RECEIVES NO OBJECTION LETTER FROM HEALTH CANADA TO BEGIN A HEALTHY ADULT PHASE 1 TRIAL FOR PPI-1011
SASKATOON-BASED BIOPHARMA COMPANY MED-LIFE DISCOVERIES RECEIVES NO OBJECTION LETTER FROM HEALTH CANADA TO BEGIN A HEALTHY ADULT PHASE 1 TRIAL FOR PPI-1011
Read More →
MLD attending Rhizokids International Conference in Alabama
MLD attending Rhizokids International Conference in Alabama
Read More →
MLD attending International Plasmalogen Conference
MLD attending International Plasmalogen Conference
Read More →
MLD attending BioPharm America
MLD attending BioPharm America
Read More →
MLD attending World Orphan Drug Congress 2022
MLD attending World Orphan Drug Congress 2022
Read More →
MLD presenting at AAIC 2022
MLD presenting at AAIC 2022
Read More →
MLD's newest manuscript describes the metabolism and tissue distribution of PPI-1011
MLD's newest manuscript describes the metabolism and tissue distribution of PPI-1011
Read More →
MLD on location in Wilmington Delaware
MLD on location in Wilmington Delaware
Read More →
MLD Obtains Analytical Cannabis License from Health Canada
MLD Obtains Analytical Cannabis License from Health Canada
Read More →
World Alzheimer's Day 2021
World Alzheimer's Day 2021
Read More →
MLD's latest publication estimating the prevalence and incidence of RCDP
MLD's latest publication estimating the prevalence and incidence of RCDP
Read More →
MLD announces new collaboration with Dr. Marie-Eve Tremblay at the University of Victoria
MLD announces new collaboration with Dr. Marie-Eve Tremblay at the University of Victoria
Read More →
Rare Disease Day 2021
Rare Disease Day 2021
Read More →
Research Collaboration with Montreal Heart Institute Research Center
Research Collaboration with Montreal Heart Institute Research Center
Read More →
MLD attending World Orphan Drug Congress
MLD attending World Orphan Drug Congress
Read More →
MLD to build new GLP laboratory facilities in Saskatoon
MLD to build new GLP laboratory facilities in Saskatoon
Read More →
MLD creates spin-out company GraySpace Therapeutics
MLD creates spin-out company GraySpace Therapeutics
Read More →
Med-Life Discoveries awarded grant by The Michael J. Fox Foundation
Med-Life Discoveries awarded grant by The Michael J. Fox Foundation
Read More →
Rare Disease Day 2020!
Rare Disease Day 2020!
Read More →
Natural History Study Update
Natural History Study Update
Read More →
Landmark Plasmalogen Precursor Paper Published
Landmark Plasmalogen Precursor Paper Published
Read More →
MLD and BML (Japan) announce distribution agreement for PanaSee™ pancreatic cancer screening test kits.
MLD and BML (Japan) announce distribution agreement for PanaSee™ pancreatic cancer screening test kits.
Read More →
MLD on location at Plasmalogen Precursor formulation site
MLD on location at Plasmalogen Precursor formulation site
Read More →
MLD to attend CTAD 2019
MLD to attend CTAD 2019
Read More →
 
 
 

Peroxisomal Disorders

Rhizomelic Chondrodysplasia Punctata (RCDP) affects fewer than 100 patients in North America. but there is #hopeforRCDP and other plasmalogen-deficient peroxisomal disorders with a first-in-class vinyl-ether plasmalogen therapy under development

 
Jackson2_original.jpg

Neurological Conditions

Plasmalogen deficiency is associated with several neurological conditions including alzheimer’s disease, parkinson’s disease, and multiple sclerosis. Therapeutically augmenting plasmalogens represents a new paradigm for the management of these diseases.

 
 
 
 
 

Literature

relevant literature, curated by our own scientific communications team

 
 
Literature
Plasmalogens and octanoylcarnitine serve as early warnings for central retinal artery occlusion.
Plasmalogens and octanoylcarnitine serve as early warnings for central retinal artery occlusion.
Read More →
Tissue-specific roles of peroxisomes revealed by expression meta-analysis.
Tissue-specific roles of peroxisomes revealed by expression meta-analysis.
Read More →
Simultaneous intake of chlorella and ascidian ethanolamine plasmalogen accelerates activation of BDNF-TrkB-CREB signaling in rats.
Simultaneous intake of chlorella and ascidian ethanolamine plasmalogen accelerates activation of BDNF-TrkB-CREB signaling in rats.
Read More →
Lipidomic analysis reveals differences in the extent of remyelination in the brain and spinal cord.
Lipidomic analysis reveals differences in the extent of remyelination in the brain and spinal cord.
Read More →
100th Blog
100th Blog
Read More →
1-O-alkyl-glycerols from squid Berryteuthis magister reduce inflammation and modify fatty acid and plasmalogen metabolism in asthma associated with obesity
1-O-alkyl-glycerols from squid Berryteuthis magister reduce inflammation and modify fatty acid and plasmalogen metabolism in asthma associated with obesity
Read More →
Niclosamide as a chemical probe for analyzing SARS-CoV-2 modulation of host cell lipid metabolism
Niclosamide as a chemical probe for analyzing SARS-CoV-2 modulation of host cell lipid metabolism
Read More →
Normal plasmalogen levels are maintained in tissues from mice with hepatocyte-specific deletion in peroxin 5.
Normal plasmalogen levels are maintained in tissues from mice with hepatocyte-specific deletion in peroxin 5.
Read More →
Antioxidative stress metabolic pathways in moderately active individuals.
Antioxidative stress metabolic pathways in moderately active individuals.
Read More →
Plasmalogen profiling in porcine brain tissues by LC-MS/MS
Plasmalogen profiling in porcine brain tissues by LC-MS/MS
Read More →
Lipidomic signature of stroke recurrence after transient ischemic attack.
Lipidomic signature of stroke recurrence after transient ischemic attack.
Read More →
Plasmalogen improves memory function by regulating neurogenesis in a mouse model of Alzheimer’s diseases.
Plasmalogen improves memory function by regulating neurogenesis in a mouse model of Alzheimer’s diseases.
Read More →
The origin of long-chain fatty acids required for de novo ether lipid/plasmalogen synthesis.
The origin of long-chain fatty acids required for de novo ether lipid/plasmalogen synthesis.
Read More →
Molecular and biophysical features of hippocampal “lipid rafts aging” are modified by dietary n-3 long-chain polyunsaturated fatty acids.
Molecular and biophysical features of hippocampal “lipid rafts aging” are modified by dietary n-3 long-chain polyunsaturated fatty acids.
Read More →
Neonatal rhizomelic chondrodysplasia punctata type 2 caused by a novel homozygous variant in the GNPAT gene.
Neonatal rhizomelic chondrodysplasia punctata type 2 caused by a novel homozygous variant in the GNPAT gene.
Read More →
Several serum lipid metabolites are associated with relapse risk in pediatric-onset multiple sclerosis.
Several serum lipid metabolites are associated with relapse risk in pediatric-onset multiple sclerosis.
Read More →
Increased n-6 polyunsaturated fatty acids indicate pro- and anti-inflammatory lipid modifications in synovial membranes with rheumatoid arthritis.
Increased n-6 polyunsaturated fatty acids indicate pro- and anti-inflammatory lipid modifications in synovial membranes with rheumatoid arthritis.
Read More →
Ether lipid-mediated antioxidant defense in Alzheimer’s disease.
Ether lipid-mediated antioxidant defense in Alzheimer’s disease.
Read More →
An Introduction to Plasmalogens in Honor of RCDP Awareness Day 2023
An Introduction to Plasmalogens in Honor of RCDP Awareness Day 2023
Read More →
Protective properties of marine alkyl glycerol ethers in chronic stress.
Protective properties of marine alkyl glycerol ethers in chronic stress.
Read More →
Reduction of ether-type glycerophospholipids, plasmalogens, by NF-ĸB signal leading to microglial activation.
Reduction of ether-type glycerophospholipids, plasmalogens, by NF-ĸB signal leading to microglial activation.
Read More →
Regulation of plasmalogen biosynthesis in mammalian cells and tissues.
Regulation of plasmalogen biosynthesis in mammalian cells and tissues.
Read More →
Overlapping and distinct features of cardiac pathology in inherited human and murine ether lipid deficiency.
Overlapping and distinct features of cardiac pathology in inherited human and murine ether lipid deficiency.
Read More →
α-synuclein and lipids in erythrocytes of Gaucher disease carriers and patients before and after enzyme replacement therapy
α-synuclein and lipids in erythrocytes of Gaucher disease carriers and patients before and after enzyme replacement therapy
Read More →
Alterations in ether lipid metabolism and the consequences for the mouse lipidome.
Alterations in ether lipid metabolism and the consequences for the mouse lipidome.
Read More →
Genetic defects in peroxisome morphogenesis (Pex11β, DLP1, and NME3) affect DHA-phospholipid metabolism.
Genetic defects in peroxisome morphogenesis (Pex11β, DLP1, and NME3) affect DHA-phospholipid metabolism.
Read More →
Transient Ca2+ entry by plasmalogen-mediated activation of receptor potential cation channel promotes AMPK activity.
Transient Ca2+ entry by plasmalogen-mediated activation of receptor potential cation channel promotes AMPK activity.
Read More →
The effect of a Pex3 mutation on hearing and lipid content of the inner ear.
The effect of a Pex3 mutation on hearing and lipid content of the inner ear.
Read More →
A case of Rhizomelic chondrodysplasia punctata in a neonate
A case of Rhizomelic chondrodysplasia punctata in a neonate
Read More →
Research advances in treatment methods and drug development for rare diseases.
Research advances in treatment methods and drug development for rare diseases.
Read More →